1. Home
  2. TECX vs EIC Comparison

TECX vs EIC Comparison

Compare TECX & EIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TECX
  • EIC
  • Stock Information
  • Founded
  • TECX 2019
  • EIC N/A
  • Country
  • TECX United States
  • EIC United States
  • Employees
  • TECX N/A
  • EIC N/A
  • Industry
  • TECX
  • EIC Finance/Investors Services
  • Sector
  • TECX
  • EIC Finance
  • Exchange
  • TECX Nasdaq
  • EIC Nasdaq
  • Market Cap
  • TECX 334.4M
  • EIC 343.8M
  • IPO Year
  • TECX 2018
  • EIC 2019
  • Fundamental
  • Price
  • TECX $22.88
  • EIC $12.90
  • Analyst Decision
  • TECX Strong Buy
  • EIC Strong Buy
  • Analyst Count
  • TECX 5
  • EIC 1
  • Target Price
  • TECX $79.00
  • EIC $17.50
  • AVG Volume (30 Days)
  • TECX 249.4K
  • EIC 323.3K
  • Earning Date
  • TECX 08-13-2025
  • EIC 08-05-2025
  • Dividend Yield
  • TECX N/A
  • EIC 19.06%
  • EPS Growth
  • TECX N/A
  • EIC N/A
  • EPS
  • TECX N/A
  • EIC 0.55
  • Revenue
  • TECX N/A
  • EIC $51,224,692.00
  • Revenue This Year
  • TECX N/A
  • EIC $37.84
  • Revenue Next Year
  • TECX N/A
  • EIC $23.33
  • P/E Ratio
  • TECX N/A
  • EIC $22.82
  • Revenue Growth
  • TECX N/A
  • EIC 68.61
  • 52 Week Low
  • TECX $13.70
  • EIC $12.46
  • 52 Week High
  • TECX $61.07
  • EIC $16.71
  • Technical
  • Relative Strength Index (RSI)
  • TECX 53.91
  • EIC 33.55
  • Support Level
  • TECX $21.41
  • EIC $12.46
  • Resistance Level
  • TECX $23.87
  • EIC $13.67
  • Average True Range (ATR)
  • TECX 1.57
  • EIC 0.28
  • MACD
  • TECX 0.08
  • EIC -0.11
  • Stochastic Oscillator
  • TECX 54.84
  • EIC 16.33

About TECX Tectonic Therapeutic Inc. Common Stock

Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.

About EIC Eagle Point Income Company Inc.

Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation. The Company seeks to achieve its investment objectives by investing in junior debt tranches of collateralized loan obligations, or "CLOs," that are collateralized by a portfolio consisting of below-investment grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.

Share on Social Networks: